These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23384373)

  • 1. Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.
    Abraham AJ; Knudsen HK; Rieckmann T; Roman PM
    J Stud Alcohol Drugs; 2013 Mar; 74(2):258-65. PubMed ID: 23384373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.
    Knudsen HK; Roman PM
    J Stud Alcohol Drugs; 2014 May; 75(3):476-85. PubMed ID: 24766760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organizing Publicly Funded Substance Use Disorder Treatment in the United States: Moving Toward a Service System Approach.
    Padwa H; Urada D; Gauthier P; Rieckmann T; Hurley B; Crèvecouer-MacPhail D; Rawson RA
    J Subst Abuse Treat; 2016 Oct; 69():9-18. PubMed ID: 27568505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth in spending on substance use disorder treatment services for the privately insured population.
    Thomas CP; Hodgkin D; Levit K; Mark TL
    Drug Alcohol Depend; 2016 Mar; 160():143-50. PubMed ID: 26781063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders.
    Knudsen HK; Abraham AJ
    Psychiatr Serv; 2012 Jan; 63(1):19-25. PubMed ID: 22227755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure.
    Knudsen HK; Abraham AJ; Oser CB
    Eval Program Plann; 2011 Nov; 34(4):375-81. PubMed ID: 21371752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled-release oxycodone admissions in public and private substance abuse treatment: associations with organizational characteristics.
    Knudsen HK; Ducharme LJ; Roman PM
    J Addict Dis; 2007; 26(1):41-50. PubMed ID: 17439867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoption and implementation of medications in addiction treatment programs.
    Knudsen HK; Abraham AJ; Roman PM
    J Addict Med; 2011 Mar; 5(1):21-7. PubMed ID: 21359109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The employment of nurses in publicly funded substance abuse treatment programs.
    Knudsen HK; Abraham AJ
    J Addict Nurs; 2012 Oct; 23(3):174-80. PubMed ID: 24135687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating the delivery of privately and publicly funded substance abuse services.
    Rawson RA; Marinelli-Casey P; Washton AM
    Behav Healthc Tomorrow; 1996 Apr; 5(2):32-5, 60-1. PubMed ID: 10157573
    [No Abstract]   [Full Text] [Related]  

  • 11. Physicians in the substance abuse treatment workforce: understanding their employment within publicly funded treatment organizations.
    Knudsen HK; Oser CB; Abraham AJ; Roman PM
    J Subst Abuse Treat; 2012 Sep; 43(2):152-60. PubMed ID: 22301083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adolescent-only substance abuse treatment: availability and adoption of components of quality.
    Knudsen HK
    J Subst Abuse Treat; 2009 Mar; 36(2):195-204. PubMed ID: 19000942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters.
    Knudsen HK; Ducharme LJ; Roman PM
    Drug Alcohol Depend; 2007 Mar; 87(2-3):164-74. PubMed ID: 16971059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of off-label medications in substance abuse treatment programs.
    Paino M; Aletraris L; Roman PM
    Subst Abus; 2020; 41(3):340-346. PubMed ID: 31361567
    [No Abstract]   [Full Text] [Related]  

  • 15. Examining trends in substance use disorder capacity and service delivery by Health Resources and Services Administration-funded health centers: A time series regression analysis.
    Pourat N; O'Masta B; Chen X; Lu C; Zhou W; Daniel M; Hoang H; Sripipatana A
    PLoS One; 2020; 15(11):e0242407. PubMed ID: 33253263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustainment of smoking cessation programs in substance use disorder treatment organizations.
    Knudsen HK; Muilenburg J; Eby LT
    Nicotine Tob Res; 2013 Jun; 15(6):1060-8. PubMed ID: 23132659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A National Study of American Indian and Alaska Native Substance Abuse Treatment: Provider and Program Characteristics.
    Rieckmann T; Moore LA; Croy CD; Novins DK; Aarons G
    J Subst Abuse Treat; 2016 Sep; 68():46-56. PubMed ID: 27431046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homelessness and publicly funded substance use disorder treatment in California, 2016-2019: Analysis of treatment needs, level of care placement, and outcomes.
    Padwa H; Bass B; Urada D
    J Subst Abuse Treat; 2022 Jun; 137():108711. PubMed ID: 35012791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of antidepressant medications in substance abuse treatment: the public-private distinction, organizational compatibility, and the environment.
    Knudsen HK; Ducharme LJ; Roman PM
    J Health Soc Behav; 2007 Jun; 48(2):195-210. PubMed ID: 17583274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substance Use Disorder Treatment Services for Women in the Veterans Health Administration.
    Timko C; Hoggatt KJ; Wu FM; Tjemsland A; Cucciare M; Rubin A; Simpson TL
    Womens Health Issues; 2017; 27(6):639-645. PubMed ID: 28602581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.